 |
|
Table 2e. Characteristics of Antiviral Agents That Are
Posted on: November 5, 2021 at 17:23:14 CT
MizzouTigerz MU
Posts:
37095
Member For:
21.15 yrs
Level:
User
M.O.B. Votes:
0
Approved or Under Evaluation for the Treatment of COVID-19
Last Updated: July 8, 2021
https://www.covid19treatmentguidelines.nih.gov/tables/table-2e/
Ivermectin
Dosing Regimens
The doses listed here are for approved indications or from reported experiences or clinical trials.
Adults:
The dose most commonly used in clinical trials is IVM 0.2–0.6 mg/kg PO given as a single dose or as a once-daily dose for up to 5 days.
Adverse Events
Generally well tolerated
Dizziness
Pruritis
GI effects (e.g., nausea, diarrhea)
Neurological AEs have been reported when IVM has been used to treat parasitic diseases, but it is not clear whether these AEs were caused by IVM or the underlying conditions.
Monitoring Parameters
Monitor for potential AEs.
Drug-Drug Interaction Potential
Minor CYP3A4 substrate
P-gp substrate
Comments and Links to Clinical Trials
Generally given on an empty stomach with water; however, administering IVM with food increases its bioavailability.2
A list of clinical trials is available here:
Ivermectin https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=ivermectin&cntry=&state=&city=&dist=&Search=Search
Last Updated: July 8, 2021
https://www.covid19treatmentguidelines.nih.gov/tables/table-2e/
Ivermectin
Dosing Regimens
The doses listed here are for approved indications or from reported experiences or clinical trials.
Adults:
The dose most commonly used in clinical trials is IVM 0.2–0.6 mg/kg PO given as a single dose or as a once-daily dose for up to 5 days.
Adverse Events
Generally well tolerated
Dizziness
Pruritis
GI effects (e.g., nausea, diarrhea)
Neurological AEs have been reported when IVM has been used to treat parasitic diseases, but it is not clear whether these AEs were caused by IVM or the underlying conditions.
Monitoring Parameters
Monitor for potential AEs.
Drug-Drug Interaction Potential
Minor CYP3A4 substrate
P-gp substrate
Comments and Links to Clinical Trials
Generally given on an empty stomach with water; however, administering IVM with food increases its bioavailability.2
A list of clinical trials is available here:
Ivermectin https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=ivermectin&cntry=&state=&city=&dist=&Search=Search
Please explain why this message is being reported.
MESSAGE THREAD
Table 2e. Characteristics of Antiviral Agents That Are - MizzouTigerz MU - 11/5 17:23:14